Haoming Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haoming Xu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Hongwei Yu
Zhejiang University
5 shared publications Wenping Xie
Institute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China
4 shared publicationsXiaomei Lv
Institute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China
4 shared publicationsLidan Ye
Institute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China
3 shared publicationsStephen W. Dusza
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
3 shared publications- Allan C. Halpern
Dermatology Service Memorial Sloan Kettering Cancer Center New York New York USA
2 shared publications
Latest Publications
- 1 August 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (8) , 1828-1830
Temporal Changes in Size and Dermoscopic Patterns of New and Existing Nevi in Adolescents
- 1 August 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (8) , 1828-1830
Temporal Changes in Size and Dermoscopic Patterns of New and Existing Nevi in Adolescents
- 19 December 2017
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 19 (3) , 363-375
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.
- 19 December 2017
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 19 (3) , 363-375
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.
- 1 December 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 77 (6) , 1133-1144.e4
Reference values for skin microanatomy: A systematic review and meta-analysis of ex vivo studies
- 1 December 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 77 (6) , 1133-1144.e4
Reference values for skin microanatomy: A systematic review and meta-analysis of ex vivo studies
- 1 October 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (10) , 990-998
Factors in Early Adolescence Associated With a Mole-Prone Phenotype in Late Adolescence
Question Can factors associated with a mole-prone phenotype in late adolescence be identified in early adolescence? Findings In this cohort study, baseline total nevus count and variability in nevus dermoscopic pattern in early adolescence was significantly associated with a mole-prone phenotype in late adolescence. Meaning Clinically recognizable factors associated with a mole-prone phenotype may facilitate the identification of a population at risk for melanoma and have implications for primary prevention strategies and skin self-examination practices. Importance Nevi are important phenotypic risk factors for melanoma in adults. Few studies have examined the constitutional and behavioral factors associated with a mole-prone phenotype in adolescents. Objective To identify host, behavioral, and dermoscopic factors in early adolescence (age, 14 years) that are associated with a mole-prone phenotype in late adolescence (age, 17 years). Design, Setting, and Participants A prospective observational cohort study from the Study of Nevi in Children was conducted from January 1, 2009, to December 31, 2014, with a 2- to 3-year follow-up. A total of 569 students from the school system in Framingham, Massachusetts, were enrolled in the 8th or 9th grade (baseline; mean [SD] age, 14.4 [0.7] years). The overall retention rate was 73.3%, and 417 students were reassessed in the 11th grade. Main Outcome and Measures Mole-prone phenotype in the 11th grade, defined as total nevus count of the back and 1 randomly selected leg in the top decile of the cohort or having any nevi greater than 5 mm in diameter. Results Of the 417 students assessed at follow-up in the 11th grade (166 females and 251 males; mean [SD] age, 17.0 [0.4] years), 111 participants (26.6%) demonstrated a mole-prone phenotype: 69 students (62.2%) with 1 nevus greater than 5 mm in diameter, 23 students (20.7%) with total nevus count in the top decile, and 19 students (17.1%) with both characteristics. On multivariate analysis, baseline total nevus count (adjusted odds ratio, 9.08; 95% CI, 4.0-23.7; P < .001) and increased variability of nevus dermoscopic pattern (adjusted odds ratio, 4.24; 95% CI, 1.36-13.25; P = .01) were associated with a mole-prone phenotype. Conclusions and Relevance This study found clinically recognizable factors associated with a mole-prone phenotype that may facilitate the identification of individuals at risk for melanoma. These findings could have implications for primary prevention strategies and help target at-risk adolescents for higher-intensity counseling about sun protection and skin self-examination.
- 1 October 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (10) , 990-998
Factors in Early Adolescence Associated With a Mole-Prone Phenotype in Late Adolescence
Question Can factors associated with a mole-prone phenotype in late adolescence be identified in early adolescence? Findings In this cohort study, baseline total nevus count and variability in nevus dermoscopic pattern in early adolescence was significantly associated with a mole-prone phenotype in late adolescence. Meaning Clinically recognizable factors associated with a mole-prone phenotype may facilitate the identification of a population at risk for melanoma and have implications for primary prevention strategies and skin self-examination practices. Importance Nevi are important phenotypic risk factors for melanoma in adults. Few studies have examined the constitutional and behavioral factors associated with a mole-prone phenotype in adolescents. Objective To identify host, behavioral, and dermoscopic factors in early adolescence (age, 14 years) that are associated with a mole-prone phenotype in late adolescence (age, 17 years). Design, Setting, and Participants A prospective observational cohort study from the Study of Nevi in Children was conducted from January 1, 2009, to December 31, 2014, with a 2- to 3-year follow-up. A total of 569 students from the school system in Framingham, Massachusetts, were enrolled in the 8th or 9th grade (baseline; mean [SD] age, 14.4 [0.7] years). The overall retention rate was 73.3%, and 417 students were reassessed in the 11th grade. Main Outcome and Measures Mole-prone phenotype in the 11th grade, defined as total nevus count of the back and 1 randomly selected leg in the top decile of the cohort or having any nevi greater than 5 mm in diameter. Results Of the 417 students assessed at follow-up in the 11th grade (166 females and 251 males; mean [SD] age, 17.0 [0.4] years), 111 participants (26.6%) demonstrated a mole-prone phenotype: 69 students (62.2%) with 1 nevus greater than 5 mm in diameter, 23 students (20.7%) with total nevus count in the top decile, and 19 students (17.1%) with both characteristics. On multivariate analysis, baseline total nevus count (adjusted odds ratio, 9.08; 95% CI, 4.0-23.7; P < .001) and increased variability of nevus dermoscopic pattern (adjusted odds ratio, 4.24; 95% CI, 1.36-13.25; P = .01) were associated with a mole-prone phenotype. Conclusions and Relevance This study found clinically recognizable factors associated with a mole-prone phenotype that may facilitate the identification of individuals at risk for melanoma. These findings could have implications for primary prevention strategies and help target at-risk adolescents for higher-intensity counseling about sun protection and skin self-examination.
- Open Access
- 27 August 2017
- Published by Society of Student Run Free Clinics in Journal of Student-Run Clinics
- Vol. 3 (1)
Containing Prescription Drug Costs at a Resource-Limited, Student-Run Clinic for the Uninsured
Prescription drug coverage and reduced medication copayments have been shown to increase medication adherence, improve health care outcomes, and reduce racial and ethnic outcome disparities. This is especially true for uninsured patients who face greater obstacles and cost-barriers in obtaining medications than their insured counterparts. For this reason, some free clinics, including our own, provide medications to patients at no out-of-pocket cost. However, the price of supplying pharmaceuticals and medical supplies at reduced or no cost is a significant financial burden to free clinics, particularly those committed to providing care to the chronically ill, a population whose monthly drug costs can be steep. In this article, we present our free clinic’s evidence-based, value-conscious approach to providing patients with prescription medications at no charge, and evaluate the cost-savings of this operation. Specifically, we highlight the following three strategies and the associated annual savings: implementation of an evidence-based formulary with drug costs available at the point-of-care; the use of Patient Drug Assistance Programs to obtain expensive, off-formulary medications; and utilization of wholesale vendors to obtain blood glucose testing supplies. We present the opportunities, limitations, and lessons learned from this ongoing effort for free clinics to optimize their own drug and medical supply coverage programs.
- 27 August 2017
- Published by Society of Student Run Free Clinics in Journal of Student-Run Clinics
- Vol. 3 (1)
Open AccessContaining Prescription Drug Costs at a Resource-Limited, Student-Run Clinic for the Uninsured
Prescription drug coverage and reduced medication copayments have been shown to increase medication adherence, improve health care outcomes, and reduce racial and ethnic outcome disparities. This is especially true for uninsured patients who face greater obstacles and cost-barriers in obtaining medications than their insured counterparts. For this reason, some free clinics, including our own, provide medications to patients at no out-of-pocket cost. However, the price of supplying pharmaceuticals and medical supplies at reduced or no cost is a significant financial burden to free clinics, particularly those committed to providing care to the chronically ill, a population whose monthly drug costs can be steep. In this article, we present our free clinic’s evidence-based, value-conscious approach to providing patients with prescription medications at no charge, and evaluate the cost-savings of this operation. Specifically, we highlight the following three strategies and the associated annual savings: implementation of an evidence-based formulary with drug costs available at the point-of-care; the use of Patient Drug Assistance Programs to obtain expensive, off-formulary medications; and utilization of wholesale vendors to obtain blood glucose testing supplies. We present the opportunities, limitations, and lessons learned from this ongoing effort for free clinics to optimize their own drug and medical supply coverage programs.
- 9 February 2017
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 33 (2) , 112-113
Improving compliance of daily sunscreen application by changing accessibility
- 9 February 2017
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 33 (2) , 112-113
Improving compliance of daily sunscreen application by changing accessibility
- Open Access
- 21 September 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 12851
Dual regulation of cytoplasmic and mitochondrial acetyl-CoA utilization for improved isoprene production in Saccharomyces cerevisiae
Microbial production of isoprene from renewable feedstock is a promising alternative to traditional petroleum-based processes. Currently, efforts to improve isoprenoid production inSaccharomyces cerevisiaemainly focus on cytoplasmic engineering, whereas comprehensive engineering of multiple subcellular compartments is rarely reported. Here, we propose dual metabolic engineering of cytoplasmic and mitochondrial acetyl-CoA utilization to boost isoprene synthesis inS. cerevisiae. This strategy increases isoprene production by 2.1-fold and 1.6-fold relative to the recombinant strains with solely mitochondrial or cytoplasmic engineering, respectively. By combining a modified reiterative recombination system for rapid pathway assembly, a two-phase culture process for dynamic metabolic regulation, and aerobic fed-batch fermentation for sufficient supply of acetyl-coA and carbon, we achieve 2527, mg l−1of isoprene, which is the highest ever reported in engineered eukaryotes. We propose this strategy as an efficient approach to enhancing isoprene production in yeast, which might open new possibilities for bioproduction of other value-added chemicals.
- 21 September 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 12851
Open AccessDual regulation of cytoplasmic and mitochondrial acetyl-CoA utilization for improved isoprene production in Saccharomyces cerevisiae
Microbial production of isoprene from renewable feedstock is a promising alternative to traditional petroleum-based processes. Currently, efforts to improve isoprenoid production inSaccharomyces cerevisiaemainly focus on cytoplasmic engineering, whereas comprehensive engineering of multiple subcellular compartments is rarely reported. Here, we propose dual metabolic engineering of cytoplasmic and mitochondrial acetyl-CoA utilization to boost isoprene synthesis inS. cerevisiae. This strategy increases isoprene production by 2.1-fold and 1.6-fold relative to the recombinant strains with solely mitochondrial or cytoplasmic engineering, respectively. By combining a modified reiterative recombination system for rapid pathway assembly, a two-phase culture process for dynamic metabolic regulation, and aerobic fed-batch fermentation for sufficient supply of acetyl-coA and carbon, we achieve 2527, mg l−1of isoprene, which is the highest ever reported in engineered eukaryotes. We propose this strategy as an efficient approach to enhancing isoprene production in yeast, which might open new possibilities for bioproduction of other value-added chemicals.
- Open Access
- 1 May 2015
- Published by American Society for Microbiology in mBio
- Vol. 6 (2) , e02556-14-e02556
Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice
In an attempt to assess the cross-protective potential of the influenza virus neuraminidase (NA) as a vaccine antigen, different subtypes of recombinant NA were expressed in a baculovirus system and used to vaccinate mice prior to lethal challenge with homologous, heterologous, or heterosubtypic viruses. Mice immunized with NA of subtype N2 were completely protected from morbidity and mortality in a homologous challenge and displayed significantly reduced viral lung titers. Heterologous challenge with a drifted strain resulted in morbidity but no mortality. Similar results were obtained for challenge experiments with N1 NA. Mice immunized with influenza B virus NA (from B/Yamagata/16/88) displayed no morbidity when sublethally infected with the homologous strain and, importantly, were completely protected from morbidity and mortality when lethally challenged with the prototype Victoria lineage strain or a more recent Victoria lineage isolate. Upon analyzing the NA content in 4 different inactivated-virus vaccine formulations from the 2013-2014 season via Western blot assay and enzyme-linked immunosorbent assay quantification, we found that the amount of NA does indeed vary across vaccine brands. We also measured hemagglutinin (HA) and NA endpoint titers in pre- and postvaccination human serum samples from individuals who received a trivalent inactivated seasonal influenza vaccine from the 2004-2005 season; the induction of NA titers was statistically less pronounced than the induction of HA titers. The demonstrated homologous and heterologous protective capacity of recombinant NA suggests that supplementing vaccine formulations with a standard amount of NA may offer increased protection against influenza virus infection.IMPORTANCEDespite the existence of vaccine prophylaxis and antiviral therapeutics, the influenza virus continues to cause morbidity and mortality in the human population, emphasizing the continued need for research in the field. While the majority of influenza vaccine strategies target the viral hemagglutinin, the immunodominant antigen on the surface of the influenza virion, antibodies against the viral neuraminidase (NA) have been correlated with less severe disease and decreased viral shedding in humans. Nevertheless, the amount of NA is not standardized in current seasonal vaccines, and the exact breadth of NA-based protection is unknown. Greater insight into the cross-protective potential of influenza virus NA as a vaccine antigen may pave the way for the development of influenza vaccines of greater breadth and efficacy.
- 1 May 2015
- Published by American Society for Microbiology in mBio
- Vol. 6 (2) , e02556-14-e02556
Open AccessVaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice
In an attempt to assess the cross-protective potential of the influenza virus neuraminidase (NA) as a vaccine antigen, different subtypes of recombinant NA were expressed in a baculovirus system and used to vaccinate mice prior to lethal challenge with homologous, heterologous, or heterosubtypic viruses. Mice immunized with NA of subtype N2 were completely protected from morbidity and mortality in a homologous challenge and displayed significantly reduced viral lung titers. Heterologous challenge with a drifted strain resulted in morbidity but no mortality. Similar results were obtained for challenge experiments with N1 NA. Mice immunized with influenza B virus NA (from B/Yamagata/16/88) displayed no morbidity when sublethally infected with the homologous strain and, importantly, were completely protected from morbidity and mortality when lethally challenged with the prototype Victoria lineage strain or a more recent Victoria lineage isolate. Upon analyzing the NA content in 4 different inactivated-virus vaccine formulations from the 2013-2014 season via Western blot assay and enzyme-linked immunosorbent assay quantification, we found that the amount of NA does indeed vary across vaccine brands. We also measured hemagglutinin (HA) and NA endpoint titers in pre- and postvaccination human serum samples from individuals who received a trivalent inactivated seasonal influenza vaccine from the 2004-2005 season; the induction of NA titers was statistically less pronounced than the induction of HA titers. The demonstrated homologous and heterologous protective capacity of recombinant NA suggests that supplementing vaccine formulations with a standard amount of NA may offer increased protection against influenza virus infection.IMPORTANCEDespite the existence of vaccine prophylaxis and antiviral therapeutics, the influenza virus continues to cause morbidity and mortality in the human population, emphasizing the continued need for research in the field. While the majority of influenza vaccine strategies target the viral hemagglutinin, the immunodominant antigen on the surface of the influenza virion, antibodies against the viral neuraminidase (NA) have been correlated with less severe disease and decreased viral shedding in humans. Nevertheless, the amount of NA is not standardized in current seasonal vaccines, and the exact breadth of NA-based protection is unknown. Greater insight into the cross-protective potential of influenza virus NA as a vaccine antigen may pave the way for the development of influenza vaccines of greater breadth and efficacy.
- 1 March 2015
- Published by Elsevier in Metabolic Engineering
- Vol. 28, 8-18
Sequential control of biosynthetic pathways for balanced utilization of metabolic intermediates in Saccharomyces cerevisiae
- 1 March 2015
- Published by Elsevier in Metabolic Engineering
- Vol. 28, 8-18
Sequential control of biosynthetic pathways for balanced utilization of metabolic intermediates in Saccharomyces cerevisiae